Venkatesan Jay's Form 4 filing
Elicio Therapeutics, Inc. (ELTX) · filed May 25, 2022
- Accession no.
- 0001601485-22-000039
- Filed
- May 25, 2022
- Trade date
- May 20-24, 2022
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $101.4K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venkatesan JayCIK 0001413350 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2022 | Common Stock | PPurchaseAcquired | +50,000 | $1.23 | +$61,500 | 1,689,257 | Direct | |
| May 24, 2022 | Common Stock | PPurchaseAcquired | +32,200 | $1.24 | +$39,928 | 1,721,457 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
President and Chief Executive Officer and Director